STOPPING HEMATOLOGICAL CANCER - Published by Mayo Clinic
The results of a Mayo Clinic study demonstrate that
a drug named imetelstat induces remissions in some
patients with myelofibrosis. This is a form of chronic
leukemia that affects the patient’s bone marrow
that is replaced by fibrosis (scar tissue) instead
of blood-producing cells.
Scientists do not yet know the exact mechanism of
action for imetelstat, but believe it interferes with the
survival and proliferation of cancer cells by inhibiting
a critical enzyme called telomerase. One of the functions
of telomerase is to repair the ends of chromosomes
called telomeres, and because cancer cells have shorter
than normal telomere size, they are particularly susceptible
to the drug.
The study results are promising. Some patients
participating in the clinical trial taking imetelstat obtained
dramatic responses, and we have seen some complete
responses (tantamount to a cure), which is almost
unheard of in this disease.
Although patients may experience relief in response
to other treatments, their bone marrow does not
usually return to normal. But in the case of this new
therapy, some of the patients participating in the trial
developed normal bone marrow.
Researchers studied imetelstat in 33 patients at
Mayo Clinic and have now followed the first 22 patients
for more than six months. Among these 22 patients,
two achieved complete remissions and three partial
remission, including reversal of bone marrow fibrosis
in four of the five patients.
Published by Mayo Clinic
Imet, you're simply repeating what End2War already brought up on this board early yesterday and this thing has been chewed up very well already if you care to go through responses and discussions under the post by ETW!!!